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Abstract
Background: The etiology of Ulcerative Colitis (UC) and Crohn's Disease (CD), considered
together as Inflammatory Bowel Diseases (IBD), involves environmental and genetic factors.
Although some genes are already known, the genetics underlying these diseases is complex and
new candidates are continuously emerging. The CD209 gene is located in a region linked previously
to IBD and a CD209 functional polymorphism (rs4804803) has been associated to other
inflammatory conditions. Our aim was to study the potential involvement of this CD209 variant in
IBD susceptibility.
Methods: We performed a case-control study with 515 CD patients, 497 UC patients and 731
healthy controls, all of them white Spaniards. Samples were typed for the CD209 single nucleotide
polymorphism (SNP) rs4804803 by TaqMan technology. Frequency comparisons were performed
using χ2 tests.
Results: No association between CD209 and UC or CD was observed initially. However,
stratification of UC patients by HLA-DR3 status, a strong protective allele, showed that carriage of
the CD209_G allele could increase susceptibility in the subgroup of HLA-DR3-positive individuals (p
= 0.03 OR = 1.77 95% CI 1.04–3.02, vs. controls).
Conclusion: A functional variant in the CD209 gene, rs4804803, does not seem to be influencing
Crohn's disease susceptibility. However, it could be involved in the etiology or pathology of
Ulcerative Colitis in HLA-DR3-positive individuals but further studies are necessary.
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Inflammatory bowel diseases comprise two distinct enti-
ties, Crohn's disease (CD) and Ulcerative Colitis (UC).
Both forms are characterized by a chronic inflammation
of the intestine, but several clinical and immunological
profiles differ between them. IBD is a multifactorial dis-
ease: environmental factors seem to be involved in disease
onset in genetically susceptible individuals. Common sus-
ceptibility genetic components exist for both diseases as
evidenced apparently by the higher risk of developing UC
in relatives of patients with CD or vice versa, but also spe-
cific genes seem to play an important role in the develop-
ment or course of each disease. For CD, CARD15
mutations are the main susceptibility factors described in
Caucasian populations [1]. On the other hand, HLA genes
show stronger effects on UC in our population, specifi-
cally HLA-DR3 seems to have a protective role in the
development of this disease [2]. However, a complex
genetic contribution exists in both diseases and new etio-
logical genes remain to be discovered.
DC-SIGN (dendritic cell-specific ICAM3-grabbing non-
integrin), also named CD209, is a type II membrane pro-
tein member of the C-type lectin receptor superfamily. It
is expressed by dendritic cells and is involved in pattern
recognition and immunoregulation [3]. The gene coding
for this protein, CD209, is located in the region 19p13,
where a linkage peak to IBD resulted from a genomewide
scan performed in Canadian families [4]. A promoter var-
iant of this gene, rs4804803, affects its transcriptional
activity in vitro and it has been associated to susceptibility
or severity to some infections [5]. Recently, this polymor-
phism has been also associated to susceptibility to a sub-
set of celiac disease patients, another inflammatory
condition sharing with IBD alterations in mucosal immu-
noregulation [6].
The aim of this study was to evaluate the relevance of the
rs4804803 polymorphism in susceptibility to IBD.
Methods
Samples
A total of 515 Crohn's disease patients and 497 ulcerative
colitis patients were collected from two Hospitals in Spain
(Hospital Clínico San Carlos, Madrid; Hospital Virgen de
las Nieves, Granada). All the patients were of Spanish
white origin. Diagnosis of UC and CD was based on
standard clinical, radiological, endoscopic, and histologi-
cal criteria. Demographic and clinical characteristics of
IBD patients are shown in Table 1. A total of 731 healthy
individuals were used as controls, all of them ethnically
matched, they were blood donors and staff members.
Written informed consent was obtained from all the par-
ticipants in the study, which was approved by the Ethical
Committee of Hospital Clínico San Carlos and the Ethical
Committee of Hospital Virgen de las Nieves.
Genotyping
One single nucleotide polymorphism (SNP), rs4804803,
was analyzed by TaqMan technology as previously
described [6]. The two SNPs studied in the CARD15 gene
were analyzed using C__11717468_20 (R702W,
rs2066844) and C__11717466_20 (G908R, rs2066845)
assays on Demand from Applied Biosystems (Foster City,
CA). The 1007fs deletion (rs2066847) in the same gene
was studied by an Assay by Design, also from Applied Bio-
systems. HLA-DR typing had been previously performed
in the UC and CD patients, respectively, as well as in con-
trols, as described before [7].
Statistical Analysis
Allelic and genotypic frequencies were compared between
groups by means of χ2 tests. Statistical analyses were per-
Table 1: Clinical characteristics of IBD patients
Ulcerative colitis
Sex (% M) 55
Mean (SD) age at onset (y) 35.1 (12.9)
Mean (SD) disease duration (y) 10.1 (7.1)
Smoking habits (%)
Never 47.1
Ex/current 52.9
Extraintestinal manifestations (%) 44.4
Disease location (%)
Left sided (including proctitis) 56.5
Extensive colitis/Pancolitis 43.5
Surgery (%) 13.8
Immunosupression (%) 24.4
Crohn's disease
Sex (% M) 49.1
Mean (SD) age at onset (y) 28.3 (12.5)
<40 (A1) 81.2
>40 (A2) 18.8
Mean (SD) disease duration (y) 9.4 (6.3)
Smoking habits (%)
Never 51.5
Ex/current 48.5
Disease location
Ileal (L1) 43.2
Colonic (L2) 17.2
Ileocolonic (L3) 35.0
Upper GI tract (L4) 4.5
Disease Behavior
Inflammatory (B1) 40.9
Stricturing (B2) 19.3
Perforating (B3) 39.8
Values are calculated only from those patients with available data. 
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Atlanta, USA).
Results
No significant differences were observed when genotypic
or allelic frequencies of the CD209 polymorphism studied
were compared between CD or UC patients and controls
(Table 2). However, the stratification of UC patients by
HLA-DR3, a genetic factor protective for UC (p = 0.00002;
OR = 0.48), showed association of the CD209 SNP with
UC only in HLA-DR3-positive patients (Table 3). When
HLA-DR3-positive patients were compared with controls a
similar association emerged (p = 0.03 OR = 1.77 95% CI
1.04–3.02). Stratification of CD patients by the presence
of CARD15 mutations did not show any significant result
(data not shown). Similarly, no association was found
after location was considered (left-sided vs. extensive col-
itis for UC, and ileal vs. colonic for CD).
Discussion
We have studied the influence of the functional polymor-
phism rs4804803 of CD209 in susceptibility to UC and
CD in the Spanish population. This gene seems to be
increasing UC susceptibility in a subgroup of patients,
those carrying HLA-DR3. It is known that HLA-DR3 is a
strong protective factor for the development of the disease
(HLA-DR3 allele: 7% in UC patients vs. 13% in controls,
p = 5.7*10-7 OR = 0.48 95% CI 0.36–0.63). Thus, HLA-
DR3-positive patients, i.e., those patients with minimal
HLA genetic contribution to susceptibility, might present
some additional susceptibility factors when compared
with HLA-DR3-negative patients. Albeit the association
described here barely reaches statistical significance, it
seems rather interesting because a most similar effect of
this gene has been recently described in other intestinal
inflammatory pathology, celiac disease [6]. The CD209
gene was found to be increasing celiac disease susceptibil-
ity only in HLA-DQ2-negative patients, i.e., those lacking
the main genetic susceptibility factor described to celiac
disease. Allele rs4804803_G seems to be involved in sus-
ceptibility to both diseases. A similar hypothesis to the
one proposed in relation to celiac disease could be work-
ing in this case; the lower transcriptional activity conse-
quence of the rs4804803_G allele would imply minor
surveillance capacity of dendritic cells and probably
increased persistence of pathogens in the gut. In these
conditions, a chronic inflammation could ensue. A role of
pathogens in initiation or maintaining of the inflamma-
tory process in IBD has been repeatedly proposed [8];
CD209 could be one of the receptors involved in the rec-
ognition of some of those pathogens. This role of CD209
in UC is compatible with the stronger impact of environ-
mental factors described in UC compared to CD [9].
However, the weak statistical significance obtained makes
necessary further analyses to confirm the influence of the
CD209 rs4804803_G allele in susceptibility to HLA-DR3
positive UC patients in other populations and specially to
investigate the involvement of this functional polymor-
phism in other chronic inflammatory conditions, mainly
in those in whose origin pathogens could be involved. As
a matter of fact, it is known that several common genes are
underlying different autoimmune diseases [10].
Ulcerative colitis has been often proposed to be a hetero-
geneous group of diseases included together because of
their clinical similarities [11]. Therefore, it is not surpris-
ing to find particular genes affecting only a previously
well-defined genetic subset of patients. This kind of find-
ings could be rewarding from a therapeutic perspective
since patients potentially responding to a specific treat-
ment could be previously selected.
Conclusion
We reported a new susceptibility factor affecting to an
ulcerative colitis subgroup of patients, those carrying
HLA-DR3. Because CD209 is involved in pathogen recog-
nition and the rs4804803_G CD209 allele results in lower
transcriptional activity, the presence of this allele might
generate an increased persistence of pathogens in the gut
and consequently a chronic inflammation.
Abbreviations
caspase recruitment domain 15 (CARD15); Crohn's Dis-
ease (CD); Human leukocyte antigen (HLA); Inflamma-
Table 2: Genotypic and allelic frequencies of CD209 rs4804803 in CD and UC patients and in controls
CD209 Controls CD UC Controls vs. CD Controls vs. UC
n = 731 % n = 515 % n = 497 %
AA 446 0.61 293 0.57 294 0.59 Overall, p = 0.27 Overall, p = 0.54
AG 251 0.34 191 0.37 184 0.37 Carriers G, p = 0.14 OR = 1.19 (0.94–1.50) Carriers G, p = 0.51 OR = 1.08 (0.85–1.37)
GG 34 0.05 31 0.06 19 0.04
A 1143 0.78 777 0.75 772 0.78 G vs. A, p = 0.11 OR = 1.17 (0.96–1.41) G vs. A, p = 0.76 OR = 1.03 (0.84–1.26)
G 319 0.22 253 0.25 222 0.22Page 3 of 4
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